Timolol
- Generic Name
- Timolol
- Brand Names
- Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
- Drug Type
- Small Molecule
- Chemical Formula
- C13H24N4O3S
- CAS Number
- 26839-75-8
- Unique Ingredient Identifier
- 5JKY92S7BR
- Background
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
- Indication
Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2009-01-07
- Lead Sponsor
- Othera Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT00753168
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT00751062
- Locations
- 🇸🇪
Pfizer Investigational Site, Uppsala, Sweden
A 6 Month Study Comparing Latanoprost With Timolol in Patients With Open Angle Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOpen Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2011-03-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 268
- Registration Number
- NCT00751127
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 294
- Registration Number
- NCT00751049
- Locations
- 🇬🇧
Pfizer Investigational Site, Sheffield, United Kingdom
Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%
- First Posted Date
- 2008-08-15
- Last Posted Date
- 2019-04-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 204
- Registration Number
- NCT00735449
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT00716859
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Comparison of Istalol™ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG)
- Conditions
- Ocular HypertensionOpen-Angle Glaucoma
- Interventions
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- Bp Consulting, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT00698945
- Locations
- 🇺🇸
North Bay Eye Associates, Inc., Petaluma, California, United States
Adjunctive Study of AL-37807 Ophthalmic Suspension
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Drug: AL-37807 ophthalmic suspension, 0.1%Other: AL-37807 ophthalmic solution vehicle
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 129
- Registration Number
- NCT00620256
- Locations
- 🇺🇸
Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas, United States
Comparison of Latanoprost Vs. Timolol
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00579969
- Locations
- 🇺🇸
UNMC Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States
Circadian Rhythms of Aqueous Humor Dynamics in Humans
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 30
- Registration Number
- NCT00572936
- Locations
- 🇺🇸
University of Nebraska Medical Center, Department of Ophthalmolgy and Visual Sciences, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.